ML385
目录号 : GC19254
ML385是一种特定的核因子红细胞2相关因子2（NRF2）抑制剂。
Cas No.:846557-71-9
Sample solution is provided at 25 µL, 10mM.
ML385 is a specific nuclear factor erythroid 2-related factor 2 (NRF2) inhibitor. ML385 binds to NRF2 and inhibits its downstream target gene expression as a probe molecule. Specifically, ML385 binds to the Neh1, the Cap ‘N’ Collar Basic Leucine Zipper (CNC-bZIP) domain of NRF2, and interferes with the binding of the V-Maf Avian Musculoaponeurotic Fibrosarcoma Oncogene Homolog G (MAFG)-NRF2 protein complex to regulatory DNA binding sequences. ML385 shows specificity and selectivity for NSCLC cells with KEAP1 mutation leading to gain of NRF2 function.[1][2]
In vitro study demonstrated that ML385 potentially inhibits NRF2 through direct interaction. The NRF2 signaling was decreased in a time-dependent manner and the maximum decline was at 72 h. A reduction in NRF2 mRNA levels was also observed. In addition, ML385 caused global inhibition of NRF2 signaling in lung cancer cells with KEAP1 mutations, and other target genes. ML385 treatment also significantly attenuated NQO1 enzyme activity and reduced GSH levels along with cellular antioxidant capacity. [2]
In vivo study of ML385 indicated that it inhibits NRF2 and showed promising anti-tumor activity. ML385 in combination with carboplatin showed a significant reduction in tumor growth compared to vehicle. Although the treatment with a single agent (either ML385 or carboplatin) led to a reduction in tumor growth, the magnitude of these effects was variable between cell lines and did not reach statistical significance. Moreover, tumor samples treated with ML385 showed a significant reduction in NRF2 protein level and its downstream target genes. Besides, the addition of ML385 decreased anisotropy in a dose-dependent manner, with an IC50 of 1.9 μM, suggesting that the NRF2-MAFG protein complex was dissociated from fluorescein-labeled ARE-DNA. [2]
References:
[1]. Xian P, et al. Mesenchymal stem cell-derived exosomes as a nanotherapeutic agent for amelioration of inflammation-induced astrocyte alterations in mice. Theranostics. 2019 Aug 14;9(20):5956-5975.
[2]. Singh A, et al. Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors. ACS Chem Biol. 2016 Nov 18;11(11):3214-3225.
| Cell experiment [1]: | |
|
Cell lines |
A549 cells |
|
Preparation Method |
A549 cells were transfected with a firefly luciferase reporter (Fluc) construct driven by a minimal TATA promoter with upstream NRF2-specific antioxidant response element (ARE) enhancer sequence from human NQO1 promoter ARE and clones stably expressing ARE-FLuc7 were screened and validated. |
|
Reaction Conditions |
Cells were cultured in the presence of ML385 (5 μM) for 48h and 72 h and measured the changes in the expression levels of NRF2 and its target genes. |
|
Applications |
ML385 treatment to A549 cells demonstrated a reduction in glutathione synthesis and recycling enzymes, members of the thioredoxin family, and glucose metabolism-related genes with a time-dependent manner. ML385 treatment significantly attenuated NQO1 enzyme activity and reduced GSH levels along with cellular antioxidant capacity. |
| Animal experiment [2]: | |
|
Animal models |
1-8-week-old C57B/6 male mice |
|
Preparation Method |
Mice received a daily intraperitoneal injection of ML385 (30 mg/kg) dissolved in PBS with 5% Dimethyl Sulfoxide (DMSO) for 7 d. |
|
Dosage form |
30 mg/kg |
|
Applications |
ML385 could inhibit Nrf2 and used to explore the mechanism of Nrf2-NF-κB signaling pathway involved in the inhibition of astrocyte activation. Mice treated with ML385 had a significant decrease in Keap1, HO-1, Nrf2, and p-P65/P-65 (P < 0.05) expression compared to Sham or Vehicle control groups. |
|
References: [1]. Singh A, et al. Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors. ACS Chem Biol. 2016 Nov 18;11(11):3214-3225. [2]. Xian P, et al. Mesenchymal stem cell-derived exosomes as a nanotherapeutic agent for amelioration of inflammation-induced astrocyte alterations in mice. Theranostics. 2019 Aug 14;9(20):5956-5975. |
|
| Cas No. | 846557-71-9 | SDF | |
| Canonical SMILES | O=C(NC1=NC(C2=CC=C(N(C(C3=C(C)C=CC=C3)=O)CC4)C4=C2)=C(C)S1)CC5=CC(OCO6)=C6C=C5 | ||
| 分子式 | C29H25N3O4S | 分子量 | 511.59 |
| 溶解度 | DMSO : ≥ 30 mg/mL (58.64 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9547 mL | 9.7735 mL | 19.5469 mL |
| 5 mM | 0.3909 mL | 1.9547 mL | 3.9094 mL |
| 10 mM | 0.1955 mL | 0.9773 mL | 1.9547 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
-
Related Biological Data
Nrf2 mediates ECH activation of the BDNF/TrkB signaling axis.(A-B) Western blot detection of nuclear Nrf2 (n=6). (C-D) Depression-like behavioral assays (n=19). (E-F) Brain tissue TUNEL for apoptosis detection.
Western blot research revealed that rats in the PSD + ECH-H group had higher levels of Nucleus-Nrf2 expression than rats in the PSD group and the PSD + ML385 (GlpBio) + ECH-H group.
Phytomedicine, 2024: 155433. PMID: 38547621 IF: 7.8996 -
Related Biological Data
DCA attenuates the expressions of key occludin and ZO-1 of TJ membrane proteins in vitro to maintain BBB integrity. (a–d)Western blotting assay of occludin and ZO-1 and the band strength of the respective protein relative to Tubulin in mouse brain. The mentioned results indicate that DCA inhibits ischemia-induced BBB destruction.
We used ML385 (GlpBio), a specific inhibitor of Nrf2 in cells, and the protective effect of DCA disappeared, indicating that DCA could alleviate oxidative stress through the PDK2-PDH-Nrf2 channel.
Oxid Med Cell Longev 2021 (2021). PMID: 34712383 IF: 6.541 -
Related Biological Data
Ellagic acid alleviated diquat-induced jejunal oxidative stress through a Nrf2 mediated signaling pathway. (A) Immunohistochemistry analysis for Nrf2 in the jejunum tissue. (B-D) NQO-1, GPX1, and HO-1 mRNA expressions in jejunum tissue.
ML385(a specific Nrf2 inhibitor) (GlpBio) was prepared in suspension in PBS with 100 µL per mouse.
iScience.2021 Sep 25;24(10):103170. PMID: 35268077 IF: 5.719 -
Related Biological Data
4-ME attenuated lipid metabolism by activating Nrf2. (E) Oil red O staining. (F) Intracellular TG content. (G–K) Quantification data of Nfr2, CD36, SREBP-1c, FASN, and PPAR-γ protein expression levels in LO2 cells
ML385 (10 µM) (GlpBio), a specific Nrf2 inhibitor, was used to treat LO2 cells.
Int J Mol Sci 23.18 (2022): 10465. PMID: 36142378 IF: 5.5999 -
Related Biological Data
Nrf2 and HO-1 inhibitors counteract the effect of Empagliflozin in suppressing Pi-induced calcification. (A,B) The Nrf2 inhibitor, ML385 (5 μM), as well as HO-1 inhibitors.
The Nrf2 inhibitor, ML385 (5 μM) (GlpBio), as well as HO-1 inhibitors
Int J Mol Sci 24.12 (2023): 10016. PMID: 37373164 IF: 5.5999